Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2019-05-02 Interim / Quarterly Rep…
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2019
2019-05-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by PTC Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2019, and mentions a conference call to discuss these results along with a slide deck. The document includes a press release as an exhibit and references the upcoming conference call and slide deck. The content is typical of an earnings release announcement and related investor communication rather than a full quarterly report or transcript. The document length is 4461 characters, which is relatively short and consistent with an earnings release or announcement rather than a full interim report or call transcript. Therefore, the best classification is Earnings Release (ER).
2019-05-02 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document length is short (2097 characters), consistent with a proxy solicitation or related materials rather than a full report. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI).
2019-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-25 English
FORM 4
Director's Dealing
2019-03-08 English
RW WD
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC regarding the withdrawal of a Form RW, which is a regulatory filing related to the withdrawal of a registration statement. It clarifies that the company mistakenly filed a Form RW instead of a Form POS ASR and requests withdrawal of the Form RW. The document is short (1328 characters) and is a regulatory communication about filings rather than a financial report or announcement of financial results. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS).
2019-03-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.